STOK
$32.87
Stoke Therapeutics, Inc.
Intraday
Recent News
Biogen Rare Disease Data And Valuation Discount Draw Investor Attention
Biogen (NasdaqGS:BIIB) reported one year results for salanersen in children with spinal muscular atrophy, showing clinical improvements and reduced neurodegeneration markers after once yearly dosing. The company outlined the initiation and design of a global Phase 3 program for salanersen in spinal muscular atrophy. Separately, Biogen and Stoke Therapeutics released data on zorevunersen indicating potential disease modification in Dravet syndrome. For investors watching NasdaqGS:BIIB, these...
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +168.87% and +3,813.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?
Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline
In recent days, Stoke Therapeutics and Biogen reported that data on the investigational Dravet syndrome medicine zorevunersen were published in The New England Journal of Medicine, alongside Stoke’s updated Phase 3 EMPEROR timeline and plans to begin a rolling FDA New Drug Application submission in the first half of 2027. The publication underscored multi‑year reductions in seizures and cognitive and behavioral gains in Dravet patients, reinforcing the clinical thesis behind Stoke’s...
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?
Dianthus Therapeutics, Inc. (DNTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.